Development of inhalation powders containing lactic acid bacteria with antimicrobial activity against Pseudomonas aeruginosa.

Cystic fibrosis Inhalation powders Lactiplantibacillus plantarum Lung microbiota Lung probiotics P. aeruginosa infection

Journal

International journal of antimicrobial agents
ISSN: 1872-7913
Titre abrégé: Int J Antimicrob Agents
Pays: Netherlands
ID NLM: 9111860

Informations de publication

Date de publication:
13 Oct 2023
Historique:
received: 12 05 2023
revised: 19 09 2023
accepted: 01 10 2023
pubmed: 16 10 2023
medline: 16 10 2023
entrez: 15 10 2023
Statut: aheadofprint

Résumé

The aim of the project was to develop and characterise powders containing a probiotic (Lactiplantibacillus plantarum [Lpb. plantarum], Lacticaseibacillus rhamnosus, or Lactobacillus acidophilus) to be administered to the lung for the containment of pathogen growth in patients with lung infections. The optimised spray drying process for the powder manufacturing was able to preserve viability of the bacteria, which decreased of only one log unit and was maintained up to 30 days. Probiotic powders showed a high respirability (42%-50% of particles had a size < 5 µm) suitable for lung deposition and were proven safe on A549 and Calu-3 cells up to a concentration of 10 This work represents a promising starting point to consider a probiotic inhalation powder a value in keeping the growth of pathogenic microflora in check during the antibiotic inhalation therapy suspension in cystic fibrosis treatment regimen. This approach could also be advantageous for interfering competitively with pathogenic bacteria and promoting the restoration of the healthy microbiota.

Identifiants

DOI: 10.1016/j.ijantimicag.2023.107001 PMID: 37839715
pubmed: 37839715
pii: S0924-8579(23)00275-3
doi: 10.1016/j.ijantimicag.2023.107001
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

107001

Informations de copyright

Copyright © 2023 The Authors. Published by Elsevier Ltd.. All rights reserved.

Auteurs

Stefania Glieca (S)

Food and Drug Department, University of Parma, Parma, Italy.

Eride Quarta (E)

Food and Drug Department, University of Parma, Parma, Italy.

Benedetta Bottari (B)

Food and Drug Department, University of Parma, Parma, Italy.

Elena Bancalari (E)

Food and Drug Department, University of Parma, Parma, Italy.

Saverio Monica (S)

Food and Drug Department, University of Parma, Parma, Italy.

Erika Scaltriti (E)

Risk Analysis and Genomic Epidemiology Unit, Istituto Zooprofilattico Sperimentale della Lombardia e dell'Emilia-Romagna, Parma, Italy.

Martina Tambassi (M)

Risk Analysis and Genomic Epidemiology Unit, Istituto Zooprofilattico Sperimentale della Lombardia e dell'Emilia-Romagna, Parma, Italy.

Lisa Flammini (L)

Food and Drug Department, University of Parma, Parma, Italy.

Simona Bertoni (S)

Food and Drug Department, University of Parma, Parma, Italy.

Annalisa Bianchera (A)

Food and Drug Department, University of Parma, Parma, Italy.

Valentina Fainardi (V)

Paediatric Clinic, Department of Medicine and Surgery, University of Parma, Parma, Italy.

Susanna Esposito (S)

Paediatric Clinic, Department of Medicine and Surgery, University of Parma, Parma, Italy.

Giovanna Pisi (G)

Cystic Fibrosis Unit, Paediatric Clinic, Az. Ospedaliera, Universitaria di Parma, Parma, Italy.

Ruggero Bettini (R)

Food and Drug Department, University of Parma, Parma, Italy; Interdepartmental Centre for Innovation in Health Products, Biopharmanet_TEC, University of Parma, Parma, Italy.

Fabio Sonvico (F)

Food and Drug Department, University of Parma, Parma, Italy; Interdepartmental Centre for Innovation in Health Products, Biopharmanet_TEC, University of Parma, Parma, Italy.

Francesca Buttini (F)

Food and Drug Department, University of Parma, Parma, Italy; Interdepartmental Centre for Innovation in Health Products, Biopharmanet_TEC, University of Parma, Parma, Italy. Electronic address: francesca.buttini@unipr.it.

Classifications MeSH